• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

DR4、DR5、DcR1 和 DcR2 型 TRAIL 受体在正常子宫内膜、非典型子宫内膜增生和子宫内膜样腺癌中的膜表达：组织微阵列研究。

Membrane expression of TRAIL receptors DR4, DR5, DcR1 and DcR2 in the normal endometrium, atypical endometrial hyperplasia and endometrioid adenocarcinoma: a tissue microarray study.

机构信息

Department of Radiotherapy, Medical University of Lodz, ul Paderewskiego 4, 93-509, Lodz, Poland,

出版信息

Arch Gynecol Obstet. 2013 Oct;288(4):889-99. doi: 10.1007/s00404-013-2840-x. Epub 2013 Apr 13.

DOI:10.1007/s00404-013-2840-x
PMID:23584885
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3778234/
Abstract

PURPOSE

To evaluate the membrane expression of DR4, DR5, DcR1 and DcR2 in the normal endometrium (NE), atypical endometrial hyperplasia (AEH) and endometrioid adenocarcinoma (EAC).

METHODS

The study comprised 197 patients: 20 NE, 18 AEH and 159 EAC. Tissue microarrays were constructed. Membrane expression of DR4, DR5, DcR1 and DcR2 was examined and presented as total score (TS).

RESULTS

In EAC, the membrane expression of DR4, DR5 and DcR2 was less common compared to NE (p < 0.001; p < 0.001; p = 0.018) and AEH (p < 0.001; p < 0.001; p = 0.004). In EAC the membrane expression of DcR1 did not differ when compared to NE (p = 0.055) and AEH (p = 0.173). A strong correlation was found between the type of endometrial tissue (NE/AEH/EAC) and the TS of DR4 (p < 0.001), DR5 (p < 0.001), DcR1 (p = 0.033) and DcR2 (p < 0.001). In EAC, the TS of DR4, DR5, DcR1 and DcR2 was not related to grading and staging. In EAC, the membrane expression of DR5, but not DR4, DcR1 and DcR2, was related to better disease-free survival (DFS). The overall survival (OS) was not related to membrane TRAIL receptors expression.

CONCLUSIONS

The membrane expression of the receptors for TRAIL DR4, DR5, DcR1 and DcR2 is greater in NE than EAC. The level of membrane staining of the receptors in EAC is not dependent on grading and staging. In EAC patients, membrane expression of DR4, DR5, DcR1 and DcR2 are not independent predictors of survival.

摘要

目的

评估正常子宫内膜（NE）、非典型子宫内膜增生（AEH）和子宫内膜样腺癌（EAC）中 DR4、DR5、DcR1 和 DcR2 的膜表达。

方法

本研究共纳入 197 例患者：20 例 NE、18 例 AEH 和 159 例 EAC。构建组织微阵列。检测 DR4、DR5、DcR1 和 DcR2 的膜表达，并以总评分（TS）表示。

结果

与 NE（p<0.001；p<0.001；p=0.018）和 AEH（p<0.001；p<0.001；p=0.004）相比，EAC 中 DR4、DR5 和 DcR2 的膜表达更为常见。与 NE（p=0.055）和 AEH（p=0.173）相比，EAC 中 DcR1 的膜表达没有差异。在子宫内膜组织类型（NE/AEH/EAC）与 DR4（p<0.001）、DR5（p<0.001）、DcR1（p=0.033）和 DcR2（p<0.001）的 TS 之间发现了很强的相关性。在 EAC 中，DR4、DR5、DcR1 和 DcR2 的 TS 与分级和分期无关。在 EAC 中，DR5 的膜表达与无病生存期（DFS）相关，但 DR4、DcR1 和 DcR2 的膜表达则不然。总生存（OS）与膜 TRAIL 受体表达无关。

结论

DR4、DR5、DcR1 和 DcR2 等 TRAIL 受体在 NE 中的膜表达高于 EAC。EAC 中受体膜染色水平与分级和分期无关。在 EAC 患者中，DR4、DR5、DcR1 和 DcR2 的膜表达均不是生存的独立预测因子。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f40b/3778234/bb36e84125cc/404_2013_2840_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f40b/3778234/d68877962a98/404_2013_2840_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f40b/3778234/ba7d1a4a9ab4/404_2013_2840_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f40b/3778234/bbda36aec06c/404_2013_2840_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f40b/3778234/7317b0fba133/404_2013_2840_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f40b/3778234/3cb25f656d81/404_2013_2840_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f40b/3778234/4e53b068a489/404_2013_2840_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f40b/3778234/bb36e84125cc/404_2013_2840_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f40b/3778234/d68877962a98/404_2013_2840_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f40b/3778234/ba7d1a4a9ab4/404_2013_2840_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f40b/3778234/bbda36aec06c/404_2013_2840_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f40b/3778234/7317b0fba133/404_2013_2840_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f40b/3778234/3cb25f656d81/404_2013_2840_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f40b/3778234/4e53b068a489/404_2013_2840_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f40b/3778234/bb36e84125cc/404_2013_2840_Fig7_HTML.jpg

相似文献

1
Membrane expression of TRAIL receptors DR4, DR5, DcR1 and DcR2 in the normal endometrium, atypical endometrial hyperplasia and endometrioid adenocarcinoma: a tissue microarray study.DR4、DR5、DcR1 和 DcR2 型 TRAIL 受体在正常子宫内膜、非典型子宫内膜增生和子宫内膜样腺癌中的膜表达：组织微阵列研究。
Arch Gynecol Obstet. 2013 Oct;288(4):889-99. doi: 10.1007/s00404-013-2840-x. Epub 2013 Apr 13.
2
Membrane expression of trail receptors DcR1 and DcR2 in the normal endometrium, endometrial atypical hyperplasia and endometrioid endometrial cancer.凋亡诱导配体（TRAIL）受体DcR1和DcR2在正常子宫内膜、子宫内膜非典型增生及子宫内膜样腺癌中的膜表达
J Obstet Gynaecol. 2014 May;34(4):346-9. doi: 10.3109/01443615.2014.889667. Epub 2014 Mar 20.
3
Membrane expression of the death ligand trail receptors DR4 and DR5 in the normal endometrium, endometrial atypical hyperplasia and endometrioid endometrial cancer.死亡配体肿瘤坏死因子相关凋亡诱导配体受体DR4和DR5在正常子宫内膜、子宫内膜非典型增生及子宫内膜样腺癌中的膜表达。
J Obstet Gynaecol. 2013 Jul;33(5):512-8. doi: 10.3109/01443615.2013.790886.
4
Hypermethylation of DcR1, DcR2, DR4, DR5 gene promoters and clinical significance in tongue carcinoma.DcR1、DcR2、DR4、DR5 基因启动子高甲基化与舌鳞癌的临床意义。
Am J Otolaryngol. 2019 Nov-Dec;40(6):102258. doi: 10.1016/j.amjoto.2019.07.002. Epub 2019 Jul 2.
5
Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation.肿瘤坏死因子相关凋亡诱导配体诱饵受体DcR1和DcR2的肿瘤特异性下调与密集的启动子高甲基化有关。
Cancer Res. 2002 Apr 1;62(7):2157-61.
6
Preparation and characterization of a set of monoclonal antibodies to TRAIL and TRAIL receptors DR4, DR5, DcR1, and DcR2.一组针对肿瘤坏死因子相关凋亡诱导配体（TRAIL）及其受体DR4、DR5、诱骗受体1（DcR1）和诱骗受体2（DcR2）的单克隆抗体的制备与表征
Hybrid Hybridomics. 2003 Apr;22(2):121-5. doi: 10.1089/153685903321948058.
7
DcR1 expression in endometrial carcinomas.DcR1 在子宫内膜癌中的表达。
Virchows Arch. 2010 Jan;456(1):39-44. doi: 10.1007/s00428-009-0855-2. Epub 2009 Nov 20.
8
Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2.诱饵受体1和2对TRAIL介导的DR5-DISC形成的差异性抑制作用。
Mol Cell Biol. 2006 Oct;26(19):7046-55. doi: 10.1128/MCB.00520-06.
9
Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL.DR4、DR5的膜表达以及半胱天冬酶-8水平（而非Mcl-1）决定了人骨髓瘤细胞对Apo2L/TRAIL的敏感性。
Exp Cell Res. 2007 Jul 1;313(11):2378-88. doi: 10.1016/j.yexcr.2007.03.018. Epub 2007 Mar 30.
10
Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types.TRAIL诱饵受体基因的异常甲基化在多种肿瘤类型中很常见。
Int J Cancer. 2004 May 1;109(5):786-92. doi: 10.1002/ijc.20041.

引用本文的文献

1
Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy.用于癌症治疗的靶向DR4和DR5的抗体及衍生物
Antibodies (Basel). 2017 Oct 25;6(4):16. doi: 10.3390/antib6040016.
2
Differential expression of senescence tumour markers and its implications on survival outcomes of breast cancer patients.衰老肿瘤标志物的差异表达及其对乳腺癌患者生存结局的影响。
PLoS One. 2019 Apr 18;14(4):e0214604. doi: 10.1371/journal.pone.0214604. eCollection 2019.

本文引用的文献

1
Construction of a tissue microarray with two millimeters cores of endometrioid endometrial cancer: factors affecting the quality of the recipient block.构建具有两毫米芯的子宫内膜样子宫内膜癌组织芯片：影响受体蜡块质量的因素
Biotech Histochem. 2012 Nov;87(8):512-8. doi: 10.3109/10520295.2012.712160. Epub 2012 Aug 22.
2
Expression of TRAIL, DR4, and DR5 in bladder cancer: correlation with response to adjuvant therapy and implications of prognosis.尿路上皮癌中 TRAIL、DR4 和 DR5 的表达：与辅助治疗反应的相关性及其预后意义。
Urology. 2012 Apr;79(4):968.e7-15. doi: 10.1016/j.urology.2011.11.011. Epub 2012 Jan 11.
3
Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer.
头颈部癌症患者中 TRAIL 和 TRAIL 受体的临床意义。
Head Neck. 2011 Sep;33(9):1278-84. doi: 10.1002/hed.21598. Epub 2010 Nov 10.
4
The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms.多激酶抑制剂索拉非尼通过不同机制诱导子宫内膜癌细胞凋亡并增强其对 TRAIL 的敏感性。
Eur J Cancer. 2010 Mar;46(4):836-50. doi: 10.1016/j.ejca.2009.12.025. Epub 2010 Jan 12.
5
DcR1 expression in endometrial carcinomas.DcR1 在子宫内膜癌中的表达。
Virchows Arch. 2010 Jan;456(1):39-44. doi: 10.1007/s00428-009-0855-2. Epub 2009 Nov 20.
6
Induction of death receptor ligand-mediated apoptosis in epithelial ovarian carcinoma: The search for sensitizing agents.诱导上皮性卵巢癌中死亡受体配体介导的细胞凋亡：寻找增敏剂。
Gynecol Oncol. 2009 Dec;115(3):438-42. doi: 10.1016/j.ygyno.2009.09.007. Epub 2009 Oct 4.
7
Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer.肿瘤坏死因子相关凋亡诱导配体（TRAIL）受体表达在乳腺癌患者中的预后意义。
J Mol Med (Berl). 2009 Oct;87(10):995-1007. doi: 10.1007/s00109-009-0510-z. Epub 2009 Aug 13.
8
Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium.国际妇产科联盟（FIGO）对外阴癌、宫颈癌和子宫内膜癌分期的修订版。
Int J Gynaecol Obstet. 2009 May;105(2):103-4. doi: 10.1016/j.ijgo.2009.02.012.
9
Is TRAIL the holy grail of cancer therapy?肿瘤坏死因子相关凋亡诱导配体（TRAIL）是癌症治疗的圣杯吗？
Apoptosis. 2009 Apr;14(4):607-23. doi: 10.1007/s10495-009-0321-2.
10
Tumor necrosis factor-related apoptosis inducing ligand-R4 decoy receptor expression is correlated with high Gleason scores, prostate-specific antigen recurrence, and decreased survival in patients with prostate carcinoma.肿瘤坏死因子相关凋亡诱导配体-R4诱饵受体表达与前列腺癌患者的高Gleason评分、前列腺特异性抗原复发及生存率降低相关。
Urol Oncol. 2008 Mar-Apr;26(2):158-65. doi: 10.1016/j.urolonc.2007.01.022. Epub 2007 Nov 19.